A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Public ClinicalTrials.gov record NCT04374136. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
Study identification
- NCT ID
- NCT04374136
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Alector Inc.
- Industry
- Enrollment
- 119 participants
Conditions and interventions
Conditions
Interventions
- AL001 Drug
- Open label - AL001 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 25 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2020
- Primary completion
- Aug 31, 2025
- Completion
- Jan 5, 2026
- Last update posted
- Jan 20, 2026
2020 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 14
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dignity Health | Phoenix | Arizona | 85013 | — |
| University of California San Diego | La Jolla | California | 92093-0648 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| Emory University | Atlanta | Georgia | 30329 | — |
| Indiana University Health Neuroscience Center | Indianapolis | Indiana | 46202 | — |
| University of Kansas Alzheimer's Disease Center | Fairway | Kansas | 66205 | — |
| Johns Hopkins University School of Medicine | Baltimore | Maryland | 21205 | — |
| Mayo Comprehensive Cancer Center - PPDS | Rochester | Minnesota | 55905 | — |
| Irving Institute for Clinical and Translational Research | New York | New York | 10032 | — |
| University Of Cincinnati Gardner Neuroscience institute | Cincinnati | Ohio | 45219 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232 | — |
| Houston Methodist Institute for Academic Medicine | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04374136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2026 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04374136 live on ClinicalTrials.gov.